Avrobio (NASDAQ:AVRO) Upgraded to “Buy” at ValuEngine

ValuEngine upgraded shares of Avrobio (NASDAQ:AVRO) from a hold rating to a buy rating in a research report report published on Thursday, ValuEngine reports.

A number of other equities research analysts also recently commented on AVRO. Cowen reaffirmed a buy rating on shares of Avrobio in a research report on Monday, July 15th. Zacks Investment Research raised shares of Avrobio from a sell rating to a hold rating and set a $25.00 target price for the company in a research report on Tuesday, July 23rd. HC Wainwright set a $40.00 target price on shares of Avrobio and gave the stock a buy rating in a research report on Tuesday, May 14th. Janney Montgomery Scott initiated coverage on shares of Avrobio in a research report on Friday, April 5th. They issued a buy rating and a $24.42 target price for the company. Finally, Mizuho initiated coverage on shares of Avrobio in a research report on Wednesday, June 26th. They set a buy rating and a $28.00 price objective for the company. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $29.40.

NASDAQ:AVRO traded down $1.07 during trading hours on Thursday, reaching $19.38. The company had a trading volume of 291,310 shares, compared to its average volume of 682,630. Avrobio has a 52 week low of $11.85 and a 52 week high of $53.70. The stock has a market cap of $512.40 million, a price-to-earnings ratio of -5.35 and a beta of 2.69. The company’s 50 day simple moving average is $17.56.

Avrobio (NASDAQ:AVRO) last posted its earnings results on Monday, May 13th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.01). As a group, research analysts forecast that Avrobio will post -2.83 EPS for the current year.

In other Avrobio news, Director Bruce Booth acquired 810,811 shares of the business’s stock in a transaction dated Friday, July 19th. The stock was purchased at an average price of $18.50 per share, with a total value of $15,000,003.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 4.70% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Pictet Asset Management Ltd. grew its position in shares of Avrobio by 0.9% during the 1st quarter. Pictet Asset Management Ltd. now owns 168,574 shares of the company’s stock valued at $3,717,000 after acquiring an additional 1,543 shares during the period. Great West Life Assurance Co. Can purchased a new position in shares of Avrobio during the 4th quarter valued at $34,000. Northern Trust Corp lifted its stake in shares of Avrobio by 2.8% during the 4th quarter. Northern Trust Corp now owns 79,211 shares of the company’s stock valued at $1,319,000 after buying an additional 2,170 shares in the last quarter. BNP Paribas Arbitrage SA purchased a new position in shares of Avrobio during the 1st quarter valued at $59,000. Finally, Strs Ohio lifted its stake in shares of Avrobio by 394.1% during the 1st quarter. Strs Ohio now owns 8,400 shares of the company’s stock valued at $185,000 after buying an additional 6,700 shares in the last quarter. 71.22% of the stock is owned by hedge funds and other institutional investors.

About Avrobio

AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.

Featured Story: How Do Tariffs Affect Trade Balances?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Avrobio (NASDAQ:AVRO)

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.